NASDAQ: RIGLRigel Pharmaceuticals Inc Stock Ownership - Who owns Rigel Pharmaceuticals?
Insider buying vs selling
Have Rigel Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Raul R. Rodriguez | CEO President | 2024-02-05 | 30,545 | $1.14 | $34.82kSell |
| David A. Santos | EVP Chief Commercial Officer | 2024-02-05 | 8,918 | $1.14 | $10.17kSell |
| Dean L. Schorno | EVP Chief Financial Officer | 2024-02-05 | 7,027 | $1.14 | $8.01kSell |
| Raul R. Rodriguez | CEO President | 2024-02-02 | 22,349 | $1.13 | $25.25kSell |
| David A. Santos | EVP Chief Commercial Officer | 2024-02-02 | 5,601 | $1.13 | $6.33kSell |
| Dean L. Schorno | EVP Chief Financial Officer | 2024-02-02 | 5,601 | $1.13 | $6.33kSell |
RIGL insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when RIGL insiders and whales buy or sell their stock.
RIGL Shareholders
What type of owners hold Rigel Pharmaceuticals Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Bvf Partners L P | 94.58% | 16,660,120 | $278.06M | Insider |
| James E. Flynn | 38.28% | 6,742,289 | $112.53M | Insider |
| Raul R. Rodriguez | 11.56% | 2,036,629 | $33.99M | Insider |
| Blackrock Inc 1 | 8.86% | 1,561,443 | $26.06M | Institution |
| Blackrock Inc | 8.86% | 1,561,443 | $26.06M | Institution |
| Armistice Capital LLC | 8.72% | 1,536,000 | $25.64M | Institution |
| Morgan Stanley | 8.31% | 1,463,499 | $24.43M | Institution |
| Invesco Ltd | 5.97% | 1,051,355 | $17.55M | Institution |
| Vanguard Group Inc | 5.59% | 985,291 | $16.44M | Institution |
| Soleus Capital Management LP | 5.31% | 934,788 | $15.60M | Institution |
RIGL vs Biotech Stocks
Rigel Pharmaceuticals Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.